Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Naunyn-Schmiedeberg's archives of pharmacology 351 (1995), S. 221-228 
    ISSN: 1432-1912
    Keywords: Key words 5-HT3 receptors ; Brainstem ; Colon ; Entorhinal cortex ; Salivary gland ; [3H]-granisetron
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  The affinities of a range of structurally diverse 5-HT3 receptor agonists and antagonists for [3H]-granisetron binding sites have been measured in membrane homogenates prepared from central and peripheral tissues of the mouse. By comparing the affinities of compounds across these tissues, the question of whether intra-species 5-HT3 receptor subtypes exist in the mouse has been addressed. In entorhinal cortex and brainstem, [3H]-granisetron bound to a single high affinity saturable binding site (Kd 0.47±0.14 and 0.60±0.05 nM; B max 20±6 and 7±2 fmol (mg protein)-1 respectively; mean± SEM; n=3). In distal and proximal colon, the specific binding of [3H]-granisetron was best fitted to a 2-site model. Kd values obtained for the high affinity site were similar to those obtained in brain tissue (distal colon: 0.47±0.09 nM, n=4; proximal colon: 0.39±0.09 nM, n=4). In salivary gland, 2-sites were evident in 2 out of 4 experiments. The Kd value (calculated from the high affinity site in the 2-site model) was approximately 10-fold less than in brain or colon (3.3±1.1 nM, n=4). B max values were 7±2, 4±1 and 71±16 fmol (mg protein)-1 for distal colon, proximal colon and salivary gland respectively. For all tissues the estimated affinity of the low affinity site was variable, and B max values could not be reliably calculated. Extensive comparative studies performed with 17 different 5-HT3 receptor agonists and antagonists in the five tissues did not reveal differences in affinity for any compound between the entorhinal cortex and the brainstem nor between the two regions of the colon. However, MDL72222, R-zacopride, d-tubocurarine, and GR80284 apparently had significantly lower affinity for colon than brain binding sites. Also, MDL72222, 2-methyl-5-HT, GR80284, 1-(m-chlorophenyl)-biguanide, metoclopramide, and granisetron had significantly lower affinity for the salivary gland binding sites than the brain binding sites. In an attempt to replicate these observations, we conducted a second study using the compounds which had shown the largest inter-tissue differences in affinity keeping as many variables as possible constant. Simultaneous comparative assays on entorhinal cortex, colon and salivary gland homogenates taken from the same mice showed that the differences that were apparent in the initial comparative study were not maintained. In conclusion, we can find no clear evidence for the existence of tissue-specific subtypes of the 5-HT3 high affinity binding site for [3H]-granisetron in the mouse in the tissues tested. However, a low affinity binding site for [3H]-granisetron was detected in peripheral tissues.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-2072
    Keywords: 5-HT3 ; Receptor ; Dopamine ; Mesolimbic
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract This article reviews current knowledge on the interaction between 5-hydroxytryptamine (5-HT), acting at 5-HT3 receptors in the CNS, and cerebral dopamine systems. Since 1987, a growing body of behavioural, neurochemical and electrophysiological evidence from animal studies has demonstrated a clear role for 5-HT3 receptors in the modulation of activity of mesolimbic and mesocortical dopamine neurones. This evidence has led to the suggestion that 5-HT3 receptor antagonists have potential as novel antipsychotic agents and may also find use in the treatment of psychoactive substance abuse. Data emerging from clinical studies generally support this hypothesis and suggest that 5-HT3 antagonists may prove to be among the first agents available to treat schizophrenia which are not dopamine D2 antagonists and hence lack their side-effect problems.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...